House Bill 722 Summary

• Authorizes licensed physicians to prescribe or recommend investigational drugs, biological products, or devices that have completed phase one clinical trials to eligible terminally ill patients without FDA approval.

• Defines eligible patients as those with terminal illness who have exhausted all FDA-approved treatments, received physician recommendation, and provided comprehensive written informed consent (or parental/guardian consent if minor).

• Permits drug manufacturers to provide investigational treatments to eligible patients but does not require them to do so; manufacturers may charge patients for manufacturing costs or provide treatments at no cost.

• Prohibits state medical and pharmacy licensing boards from revoking or denying renewal of physician or pharmacist licenses based solely on recommending investigational drugs to eligible patients, with limited exception for gross negligence or willful misconduct.

• Provides immunity from civil liability for manufacturers, prescribers, dispensers, and administrators of investigational drugs used under this act, except in cases of gross negligence or willful misconduct; effective July 1, 2015.